Compare ERC & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERC | EOLS |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.9M | 284.3M |
| IPO Year | N/A | 2018 |
| Metric | ERC | EOLS |
|---|---|---|
| Price | $9.11 | $5.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 70.4K | ★ 651.1K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 8.37% | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ 0.72 | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | N/A | $13.27 |
| Revenue Next Year | N/A | $17.62 |
| P/E Ratio | $12.77 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $8.72 | $3.86 |
| 52 Week High | $9.78 | $12.16 |
| Indicator | ERC | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 66.93 |
| Support Level | $8.90 | $4.02 |
| Resistance Level | $9.44 | $5.52 |
| Average True Range (ATR) | 0.09 | 0.27 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 23.78 | 83.15 |
Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.